Rigel Optimistic On Fostamatinib Despite Narrow Phase III Benefit

Rigel's SYK inhibitor fostamatinib met the primary endpoint in the first of two pivotal Phase III trials in chronic ITP, but yielded a treatment effect in only 18% of the patients. CEO Raul Rodriguez discussed the data in an interview.

Rigel Pharmaceuticals Inc. has produced positive Phase III data with the platelet drug fostamatinib in chronic/persistent immune thrombocytopenia, putting the oral spleen tyrosine kinase (SYK) inhibitor on footing for a potential approval after the company failed to successfully develop the drug in rheumatoid arthritis.

The South San Francisco, California company reported results from the first of two identical trials in Rigel's Phase III FIT clinical program on Aug. 30. The first FIT study met...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By 

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

 
• By 

Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.